{"id":340,"date":"2020-03-23T07:56:25","date_gmt":"2020-03-23T14:56:25","guid":{"rendered":"https:\/\/derm-biomepharmaceuticals.com\/?p=340"},"modified":"2020-03-23T08:02:20","modified_gmt":"2020-03-23T15:02:20","slug":"derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/","title":{"rendered":"Derm-Biome Pharmaceuticals, Inc. meldet positive Ergebnisse einer pr\u00e4klinischen Studie bei atopischer Dermatitis"},"content":{"rendered":"<p>[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221;][vc_column][vc_column_text]<\/p>\n<div class=\"page\" title=\"Seite 1\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>VANCOUVER, British Columbia, 24. M\u00e4rz 2020 (GLOBE NEWSWIRE) \u2013 Derm-Biome Pharmaceuticals, Inc, ein privates biopharmazeutisches Start-up-Unternehmen mit Sitz in Vancouver, das sich auf Hautgesundheit und gesundes Altern konzentriert, freut sich bekannt zu geben, dass eines seiner topischen Medikamente bedeutende Ergebnisse erzielt hat und dosisabh\u00e4ngige Hemmwirkungen in einem gut etablierten Mausmodell f\u00fcr atopische Dermatitis (AD). AD (Ekzem) ist eine chronisch entz\u00fcndliche Hauterkrankung, die h\u00e4ufig mit Depressionen und einer verminderten Lebensqualit\u00e4t einhergeht. Der weltweite AD-Behandlungsmarkt wird voraussichtlich ein gesundes Wachstum verzeichnen, wobei die Prognosen bis 2027 bei bis zu $18,3 Milliarden US-Dollar liegen.<\/p>\n<p>Gordon Eberwein, CEO von Derm-Biome: \u201eWir sind sehr gespannt auf die Ergebnisse dieser Studie. Es besteht immer noch ein erheblicher ungedeckter Bedarf bei der Behandlung von atopischer Dermatitis, insbesondere bei atopischer Dermatitis bei Kindern, bei der AD 15% bis 20% bei Kindern beeintr\u00e4chtigt. Wir sehen eine gro\u00dfe Chance f\u00fcr ein Medikament, das auf einem Naturprodukt basiert, gut vertr\u00e4glich ist und bei topischer Anwendung wirksam ist, nicht nur zur Behandlung chronisch entz\u00fcndlicher Hauterkrankungen, sondern auch, um deren Entwicklung durch fr\u00fchzeitiges Eingreifen potenziell zu verhindern.\u201c<\/p>\n<p>Die Verbindung hemmt die entz\u00fcndungsf\u00f6rdernde Zytokinproduktion und zielt auf mehrere aktive Signalwege ab, die m\u00f6glicherweise f\u00fcr die Behandlung von AD und ihren verschiedenen Ph\u00e4notypen von entscheidender Bedeutung sind. Es reguliert entz\u00fcndungshemmende Mediatoren einschlie\u00dflich Interferonen und anderen entz\u00fcndlichen Zytokinen hoch und steigert die Expression von Proteinen, die f\u00fcr die Aufrechterhaltung einer wirksamen Hautbarriere wichtig sind, deren Fehlen in der Haut stark mit der Entwicklung von AD zusammenh\u00e4ngt. Die Verbindung f\u00f6rdert auch die Diversit\u00e4t des Mikrobioms, indem sie das Wachstum bestimmter Staphylococcus-Arten hemmt, Bakterien, die die Haut von AD-Patienten besiedeln.<\/p>\n<p>Derm-Biome CSO Dr. Poul Sorensen: \u201eEntz\u00fcndungen tragen wesentlich zu k\u00f6rperlichen Gesundheitsproblemen und chronischen Krankheiten wie atopischer Dermatitis bei.\u201c Wir sind sehr gespannt auf die Aussichten f\u00fcr unsere nat\u00fcrlichen Verbindungen und ihre weitreichenden entz\u00fcndungshemmenden Eigenschaften.\u201c<\/p>\n<p>Die Ergebnisse einer Hautvertr\u00e4glichkeits- und Pharmakokinetikstudie an Schweinen zeigten, dass die Verbindung gut vertr\u00e4glich war. Ein kanadischer Antrag f\u00fcr eine klinische Studie (CTA) wird bis Mitte 2020 eingereicht, ein Antrag f\u00fcr ein neues Pr\u00fcfpr\u00e4parat folgt. Eine vorl\u00e4ufige Patentanmeldung wurde eingereicht.<\/p>\n<p><strong>\u00dcber Derm-Biome Pharmaceuticals, Inc<\/strong><\/p>\n<p>Derm-Biome Pharmaceuticals, Inc. ist ein privates pr\u00e4klinisches biopharmazeutisches Unternehmen mit \u00fcber 40 nat\u00fcrlichen Derivaten, Salzen und Co-Kristallen, das sich der Verbesserung der Hautgesundheit und eines gesunden Alterns widmet. Unsere Verbindungen sind gut vertr\u00e4glich und weisen neuartige entz\u00fcndungshemmende, antioxidative, antimikrobielle und antitumorale Eigenschaften auf.<\/p>\n<p><strong>Kontakt<\/strong><br \/>\nInvestorenanfragen:<br \/>\nGordon Eberwein<br \/>\n<a href=\"mailto:geberwein@derm-biome.com\">geberwein@derm-biome.com<\/a><br \/>\n<a href=\"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/\">https:\/\/derm-biomepharmaceuticals.com\/<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>","protected":false},"excerpt":{"rendered":"<p>[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221;][vc_column][vc_column_text] VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) &#8212; Derm-Biome Pharmaceuticals, Inc, a private Vancouver based start-up biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established [&hellip;]<\/p>","protected":false},"author":2,"featured_media":342,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[5],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis - Derm-Biome Pharmaceuticals Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis - Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"og:description\" content=\"[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221;][vc_column][vc_column_text] VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) &#8212; Derm-Biome Pharmaceuticals, Inc, a private Vancouver based start-up biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/\" \/>\n<meta property=\"og:site_name\" content=\"Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-23T14:56:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-03-23T15:02:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/03\/Announcement-Photo-2020Mar.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"539\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Derm-Biome Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschrieben von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Derm-Biome Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/\"},\"author\":{\"name\":\"Derm-Biome Admin\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\"},\"headline\":\"Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis\",\"datePublished\":\"2020-03-23T14:56:25+00:00\",\"dateModified\":\"2020-03-23T15:02:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/\"},\"wordCount\":441,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/03\/Announcement-Photo-2020Mar.jpg\",\"articleSection\":[\"Recent News\"],\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/\",\"name\":\"Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis - Derm-Biome Pharmaceuticals Inc.\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/03\/Announcement-Photo-2020Mar.jpg\",\"datePublished\":\"2020-03-23T14:56:25+00:00\",\"dateModified\":\"2020-03-23T15:02:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#primaryimage\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/03\/Announcement-Photo-2020Mar.jpg\",\"contentUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/03\/Announcement-Photo-2020Mar.jpg\",\"width\":1000,\"height\":539},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/derm-biomepharmaceuticals.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"name\":\"Derm-Biome Pharmaceuticals Inc.\",\"description\":\"Startup Biopharmaceutical Company\",\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\",\"name\":\"Derm-Biome Pharmaceuticals\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"contentUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"width\":450,\"height\":200,\"caption\":\"Derm-Biome Pharmaceuticals\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\",\"name\":\"Derm-Biome Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"caption\":\"Derm-Biome Admin\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis - Derm-Biome Pharmaceuticals Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/","og_locale":"de_DE","og_type":"article","og_title":"Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis - Derm-Biome Pharmaceuticals Inc.","og_description":"[vc_row css_animation=&#8221;&#8221; row_type=&#8221;row&#8221; use_row_as_full_screen_section=&#8221;no&#8221; type=&#8221;full_width&#8221; angled_section=&#8221;no&#8221; text_align=&#8221;left&#8221; background_image_as_pattern=&#8221;without_pattern&#8221;][vc_column][vc_column_text] VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) &#8212; Derm-Biome Pharmaceuticals, Inc, a private Vancouver based start-up biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established [&hellip;]","og_url":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/","og_site_name":"Derm-Biome Pharmaceuticals Inc.","article_published_time":"2020-03-23T14:56:25+00:00","article_modified_time":"2020-03-23T15:02:20+00:00","og_image":[{"width":1000,"height":539,"url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/03\/Announcement-Photo-2020Mar.jpg","type":"image\/jpeg"}],"author":"Derm-Biome Admin","twitter_card":"summary_large_image","twitter_misc":{"Geschrieben von":"Derm-Biome Admin","Gesch\u00e4tzte Lesezeit":"2 Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#article","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/"},"author":{"name":"Derm-Biome Admin","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d"},"headline":"Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis","datePublished":"2020-03-23T14:56:25+00:00","dateModified":"2020-03-23T15:02:20+00:00","mainEntityOfPage":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/"},"wordCount":441,"commentCount":0,"publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#primaryimage"},"thumbnailUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/03\/Announcement-Photo-2020Mar.jpg","articleSection":["Recent News"],"inLanguage":"de-DE","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/","url":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/","name":"Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis - Derm-Biome Pharmaceuticals Inc.","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#primaryimage"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#primaryimage"},"thumbnailUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/03\/Announcement-Photo-2020Mar.jpg","datePublished":"2020-03-23T14:56:25+00:00","dateModified":"2020-03-23T15:02:20+00:00","breadcrumb":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#primaryimage","url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/03\/Announcement-Photo-2020Mar.jpg","contentUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2020\/03\/Announcement-Photo-2020Mar.jpg","width":1000,"height":539},{"@type":"BreadcrumbList","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/derm-biomepharmaceuticals.com\/"},{"@type":"ListItem","position":2,"name":"Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis"}]},{"@type":"WebSite","@id":"https:\/\/derm-biomepharmaceuticals.com\/#website","url":"https:\/\/derm-biomepharmaceuticals.com\/","name":"Derm-Biome Pharmaceuticals Inc.","description":"Startup Biopharmaceutical Company","publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization","name":"Derm-Biome Pharmaceuticals","url":"https:\/\/derm-biomepharmaceuticals.com\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/","url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","contentUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","width":450,"height":200,"caption":"Derm-Biome Pharmaceuticals"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d","name":"Derm-Biome Admin","image":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","caption":"Derm-Biome Admin"}}]}},"_links":{"self":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts\/340"}],"collection":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/comments?post=340"}],"version-history":[{"count":1,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts\/340\/revisions"}],"predecessor-version":[{"id":341,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/posts\/340\/revisions\/341"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/media\/342"}],"wp:attachment":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/media?parent=340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/categories?post=340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/de_de_formal\/wp-json\/wp\/v2\/tags?post=340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}